nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCC1—Epirubicin—urinary bladder cancer	0.0829	0.13	CbGbCtD
Vemurafenib—ABCC1—Etoposide—urinary bladder cancer	0.0646	0.101	CbGbCtD
Vemurafenib—ABCG2—Fluorouracil—urinary bladder cancer	0.0518	0.0812	CbGbCtD
Vemurafenib—ABCG2—Carboplatin—urinary bladder cancer	0.0515	0.0808	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—urinary bladder cancer	0.0441	0.0691	CbGbCtD
Vemurafenib—ABCG2—Cisplatin—urinary bladder cancer	0.044	0.069	CbGbCtD
Vemurafenib—ABCG2—Etoposide—urinary bladder cancer	0.0432	0.0678	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—urinary bladder cancer	0.0427	0.0669	CbGbCtD
Vemurafenib—ALB—Fluorouracil—urinary bladder cancer	0.0357	0.056	CbGbCtD
Vemurafenib—CYP3A4—Thiotepa—urinary bladder cancer	0.0344	0.054	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—urinary bladder cancer	0.0295	0.0462	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—urinary bladder cancer	0.0286	0.0448	CbGbCtD
Vemurafenib—CYP1A2—Fluorouracil—urinary bladder cancer	0.0214	0.0335	CbGbCtD
Vemurafenib—ALB—Methotrexate—urinary bladder cancer	0.0197	0.0309	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—urinary bladder cancer	0.0178	0.028	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—urinary bladder cancer	0.01	0.0157	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—urinary bladder cancer	0.00934	0.0146	CbGbCtD
Vemurafenib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00637	0.00999	CbGbCtD
Vemurafenib—BRAF—prostate gland—urinary bladder cancer	0.00536	0.0887	CbGeAlD
Vemurafenib—CYP1A2—urine—urinary bladder cancer	0.00396	0.0656	CbGeAlD
Vemurafenib—RAF1—prostate gland—urinary bladder cancer	0.00357	0.0591	CbGeAlD
Vemurafenib—RAF1—seminal vesicle—urinary bladder cancer	0.00302	0.05	CbGeAlD
Vemurafenib—CYP3A4—urine—urinary bladder cancer	0.00287	0.0475	CbGeAlD
Vemurafenib—CYP2D6—urine—urinary bladder cancer	0.00282	0.0467	CbGeAlD
Vemurafenib—BRAF—vagina—urinary bladder cancer	0.00265	0.0438	CbGeAlD
Vemurafenib—RAF1—epithelium—urinary bladder cancer	0.00262	0.0434	CbGeAlD
Vemurafenib—RAF1—smooth muscle tissue—urinary bladder cancer	0.00253	0.0419	CbGeAlD
Vemurafenib—ORM1—prostate gland—urinary bladder cancer	0.00247	0.0408	CbGeAlD
Vemurafenib—RAF1—renal system—urinary bladder cancer	0.00243	0.0403	CbGeAlD
Vemurafenib—RAF1—urethra—urinary bladder cancer	0.00239	0.0396	CbGeAlD
Vemurafenib—RAF1—female reproductive system—urinary bladder cancer	0.00195	0.0323	CbGeAlD
Vemurafenib—ABCC1—prostate gland—urinary bladder cancer	0.00178	0.0295	CbGeAlD
Vemurafenib—RAF1—vagina—urinary bladder cancer	0.00176	0.0292	CbGeAlD
Vemurafenib—BRAF—lymph node—urinary bladder cancer	0.00171	0.0283	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—urinary bladder cancer	0.0017	1	CrCbGaD
Vemurafenib—ABCC1—seminal vesicle—urinary bladder cancer	0.00151	0.025	CbGeAlD
Vemurafenib—ABCG2—prostate gland—urinary bladder cancer	0.00148	0.0245	CbGeAlD
Vemurafenib—ORM1—female reproductive system—urinary bladder cancer	0.00135	0.0223	CbGeAlD
Vemurafenib—ABCG2—seminal vesicle—urinary bladder cancer	0.00125	0.0207	CbGeAlD
Vemurafenib—ABCC1—urethra—urinary bladder cancer	0.00119	0.0198	CbGeAlD
Vemurafenib—RAF1—lymph node—urinary bladder cancer	0.00114	0.0189	CbGeAlD
Vemurafenib—ABCG2—urethra—urinary bladder cancer	0.000989	0.0164	CbGeAlD
Vemurafenib—CYP1A2—renal system—urinary bladder cancer	0.000969	0.016	CbGeAlD
Vemurafenib—ABCC1—vagina—urinary bladder cancer	0.000881	0.0146	CbGeAlD
Vemurafenib—ORM1—lymph node—urinary bladder cancer	0.000787	0.013	CbGeAlD
Vemurafenib—ABCG2—vagina—urinary bladder cancer	0.000729	0.0121	CbGeAlD
Vemurafenib—CYP3A4—renal system—urinary bladder cancer	0.000701	0.0116	CbGeAlD
Vemurafenib—ALB—lymph node—urinary bladder cancer	0.00069	0.0114	CbGeAlD
Vemurafenib—CYP2D6—renal system—urinary bladder cancer	0.00069	0.0114	CbGeAlD
Vemurafenib—ABCC1—lymph node—urinary bladder cancer	0.00057	0.00943	CbGeAlD
Vemurafenib—CYP3A4—female reproductive system—urinary bladder cancer	0.000562	0.0093	CbGeAlD
Vemurafenib—CYP2D6—female reproductive system—urinary bladder cancer	0.000553	0.00915	CbGeAlD
Vemurafenib—ABCG2—lymph node—urinary bladder cancer	0.000472	0.00781	CbGeAlD
Vemurafenib—Alopecia—Cisplatin—urinary bladder cancer	0.000356	0.00282	CcSEcCtD
Vemurafenib—Skin disorder—Thiotepa—urinary bladder cancer	0.000355	0.00281	CcSEcCtD
Vemurafenib—Malnutrition—Cisplatin—urinary bladder cancer	0.000351	0.00278	CcSEcCtD
Vemurafenib—Erythema—Cisplatin—urinary bladder cancer	0.000351	0.00278	CcSEcCtD
Vemurafenib—Erythema multiforme—Etoposide—urinary bladder cancer	0.000349	0.00276	CcSEcCtD
Vemurafenib—Rash maculo-papular—Doxorubicin—urinary bladder cancer	0.000347	0.00274	CcSEcCtD
Vemurafenib—Eye disorder—Etoposide—urinary bladder cancer	0.000345	0.00273	CcSEcCtD
Vemurafenib—Neoplasm—Doxorubicin—urinary bladder cancer	0.000345	0.00273	CcSEcCtD
Vemurafenib—Cardiac disorder—Etoposide—urinary bladder cancer	0.000343	0.00271	CcSEcCtD
Vemurafenib—Photosensitivity—Epirubicin—urinary bladder cancer	0.000341	0.0027	CcSEcCtD
Vemurafenib—Angiopathy—Etoposide—urinary bladder cancer	0.000335	0.00265	CcSEcCtD
Vemurafenib—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000333	0.00263	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000333	0.00263	CcSEcCtD
Vemurafenib—Chills—Etoposide—urinary bladder cancer	0.000331	0.00262	CcSEcCtD
Vemurafenib—Cough—Gemcitabine—urinary bladder cancer	0.000328	0.0026	CcSEcCtD
Vemurafenib—Alopecia—Etoposide—urinary bladder cancer	0.000326	0.00258	CcSEcCtD
Vemurafenib—Arthralgia—Gemcitabine—urinary bladder cancer	0.00032	0.00254	CcSEcCtD
Vemurafenib—Myalgia—Gemcitabine—urinary bladder cancer	0.00032	0.00254	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000318	0.00252	CcSEcCtD
Vemurafenib—Decreased appetite—Thiotepa—urinary bladder cancer	0.000317	0.00251	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000315	0.0025	CcSEcCtD
Vemurafenib—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000315	0.0025	CcSEcCtD
Vemurafenib—Myalgia—Fluorouracil—urinary bladder cancer	0.000315	0.00249	CcSEcCtD
Vemurafenib—Fatigue—Thiotepa—urinary bladder cancer	0.000315	0.00249	CcSEcCtD
Vemurafenib—Dysgeusia—Etoposide—urinary bladder cancer	0.000315	0.00249	CcSEcCtD
Vemurafenib—Constipation—Thiotepa—urinary bladder cancer	0.000312	0.00247	CcSEcCtD
Vemurafenib—Back pain—Etoposide—urinary bladder cancer	0.000311	0.00246	CcSEcCtD
Vemurafenib—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000307	0.00243	CcSEcCtD
Vemurafenib—Infection—Gemcitabine—urinary bladder cancer	0.000305	0.00242	CcSEcCtD
Vemurafenib—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000302	0.00239	CcSEcCtD
Vemurafenib—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000301	0.00239	CcSEcCtD
Vemurafenib—Infection—Fluorouracil—urinary bladder cancer	0.0003	0.00238	CcSEcCtD
Vemurafenib—Pain in extremity—Epirubicin—urinary bladder cancer	0.000299	0.00237	CcSEcCtD
Vemurafenib—Myalgia—Cisplatin—urinary bladder cancer	0.000299	0.00237	CcSEcCtD
Vemurafenib—Skin disorder—Gemcitabine—urinary bladder cancer	0.000298	0.00236	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000297	0.00235	CcSEcCtD
Vemurafenib—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000296	0.00235	CcSEcCtD
Vemurafenib—Body temperature increased—Thiotepa—urinary bladder cancer	0.000289	0.00229	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000288	0.00228	CcSEcCtD
Vemurafenib—Hypotension—Gemcitabine—urinary bladder cancer	0.000287	0.00227	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000286	0.00227	CcSEcCtD
Vemurafenib—Infection—Cisplatin—urinary bladder cancer	0.000284	0.00225	CcSEcCtD
Vemurafenib—Hypotension—Fluorouracil—urinary bladder cancer	0.000282	0.00223	CcSEcCtD
Vemurafenib—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000281	0.00222	CcSEcCtD
Vemurafenib—Cough—Etoposide—urinary bladder cancer	0.00028	0.00222	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00028	0.00222	CcSEcCtD
Vemurafenib—Skin disorder—Cisplatin—urinary bladder cancer	0.000278	0.0022	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000277	0.00219	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000275	0.00218	CcSEcCtD
Vemurafenib—Dry skin—Epirubicin—urinary bladder cancer	0.000274	0.00217	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—urinary bladder cancer	0.000274	0.00217	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000272	0.00215	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000269	0.00213	CcSEcCtD
Vemurafenib—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000269	0.00213	CcSEcCtD
Vemurafenib—Hypotension—Cisplatin—urinary bladder cancer	0.000268	0.00212	CcSEcCtD
Vemurafenib—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000267	0.00211	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000265	0.0021	CcSEcCtD
Vemurafenib—Fatigue—Gemcitabine—urinary bladder cancer	0.000265	0.0021	CcSEcCtD
Vemurafenib—Constipation—Gemcitabine—urinary bladder cancer	0.000263	0.00208	CcSEcCtD
Vemurafenib—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000263	0.00208	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000262	0.00208	CcSEcCtD
Vemurafenib—Asthenia—Thiotepa—urinary bladder cancer	0.000262	0.00207	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000261	0.00207	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000261	0.00206	CcSEcCtD
Vemurafenib—Infection—Etoposide—urinary bladder cancer	0.000261	0.00206	CcSEcCtD
Vemurafenib—Pruritus—Thiotepa—urinary bladder cancer	0.000258	0.00205	CcSEcCtD
Vemurafenib—Eosinophilia—Epirubicin—urinary bladder cancer	0.000256	0.00203	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—urinary bladder cancer	0.000255	0.00202	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—urinary bladder cancer	0.000254	0.00201	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000252	0.002	CcSEcCtD
Vemurafenib—Diarrhoea—Thiotepa—urinary bladder cancer	0.00025	0.00198	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000249	0.00197	CcSEcCtD
Vemurafenib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000249	0.00197	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000247	0.00196	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—urinary bladder cancer	0.000246	0.00195	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—urinary bladder cancer	0.000246	0.00195	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—urinary bladder cancer	0.000245	0.00194	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000244	0.00193	CcSEcCtD
Vemurafenib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000243	0.00192	CcSEcCtD
Vemurafenib—Dizziness—Thiotepa—urinary bladder cancer	0.000241	0.00191	CcSEcCtD
Vemurafenib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000239	0.00189	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000237	0.00188	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000236	0.00187	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—urinary bladder cancer	0.000234	0.00185	CcSEcCtD
Vemurafenib—Vomiting—Thiotepa—urinary bladder cancer	0.000232	0.00184	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—urinary bladder cancer	0.000231	0.00183	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—urinary bladder cancer	0.000231	0.00183	CcSEcCtD
Vemurafenib—Rash—Thiotepa—urinary bladder cancer	0.00023	0.00182	CcSEcCtD
Vemurafenib—Dermatitis—Thiotepa—urinary bladder cancer	0.00023	0.00182	CcSEcCtD
Vemurafenib—Headache—Thiotepa—urinary bladder cancer	0.000229	0.00181	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000229	0.00181	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—urinary bladder cancer	0.000228	0.00181	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000226	0.00179	CcSEcCtD
Vemurafenib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000226	0.00179	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—urinary bladder cancer	0.000226	0.00179	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000226	0.00179	CcSEcCtD
Vemurafenib—Constipation—Etoposide—urinary bladder cancer	0.000224	0.00178	CcSEcCtD
Vemurafenib—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000222	0.00176	CcSEcCtD
Vemurafenib—Asthenia—Gemcitabine—urinary bladder cancer	0.00022	0.00175	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000218	0.00173	CcSEcCtD
Vemurafenib—Pruritus—Gemcitabine—urinary bladder cancer	0.000217	0.00172	CcSEcCtD
Vemurafenib—Nausea—Thiotepa—urinary bladder cancer	0.000217	0.00172	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—urinary bladder cancer	0.000216	0.00171	CcSEcCtD
Vemurafenib—Pruritus—Fluorouracil—urinary bladder cancer	0.000214	0.00169	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000213	0.00169	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—urinary bladder cancer	0.000213	0.00169	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000211	0.00167	CcSEcCtD
Vemurafenib—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000211	0.00167	CcSEcCtD
Vemurafenib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00021	0.00166	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000209	0.00166	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000209	0.00166	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—urinary bladder cancer	0.000207	0.00164	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—urinary bladder cancer	0.000207	0.00164	CcSEcCtD
Vemurafenib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000207	0.00164	CcSEcCtD
Vemurafenib—Asthenia—Cisplatin—urinary bladder cancer	0.000205	0.00163	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000205	0.00163	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000204	0.00161	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000203	0.00161	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—urinary bladder cancer	0.000201	0.00159	CcSEcCtD
Vemurafenib—Dizziness—Fluorouracil—urinary bladder cancer	0.0002	0.00158	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000199	0.00158	CcSEcCtD
Vemurafenib—Chills—Methotrexate—urinary bladder cancer	0.000198	0.00157	CcSEcCtD
Vemurafenib—Diarrhoea—Cisplatin—urinary bladder cancer	0.000196	0.00155	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000196	0.00155	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—urinary bladder cancer	0.000195	0.00155	CcSEcCtD
Vemurafenib—Vomiting—Gemcitabine—urinary bladder cancer	0.000195	0.00155	CcSEcCtD
Vemurafenib—Rash—Gemcitabine—urinary bladder cancer	0.000194	0.00153	CcSEcCtD
Vemurafenib—Dermatitis—Gemcitabine—urinary bladder cancer	0.000193	0.00153	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—urinary bladder cancer	0.000193	0.00153	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—urinary bladder cancer	0.000193	0.00153	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—urinary bladder cancer	0.000192	0.00152	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—urinary bladder cancer	0.000192	0.00152	CcSEcCtD
Vemurafenib—Headache—Gemcitabine—urinary bladder cancer	0.000192	0.00152	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000192	0.00152	CcSEcCtD
Vemurafenib—Vomiting—Fluorouracil—urinary bladder cancer	0.000192	0.00152	CcSEcCtD
Vemurafenib—Rash—Fluorouracil—urinary bladder cancer	0.00019	0.00151	CcSEcCtD
Vemurafenib—Dermatitis—Fluorouracil—urinary bladder cancer	0.00019	0.00151	CcSEcCtD
Vemurafenib—Headache—Fluorouracil—urinary bladder cancer	0.000189	0.0015	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000189	0.00149	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—urinary bladder cancer	0.000188	0.00149	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—urinary bladder cancer	0.000188	0.00149	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000188	0.00149	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—urinary bladder cancer	0.000188	0.00149	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000186	0.00148	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—urinary bladder cancer	0.000186	0.00147	CcSEcCtD
Vemurafenib—Chills—Epirubicin—urinary bladder cancer	0.000186	0.00147	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—urinary bladder cancer	0.000186	0.00147	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—urinary bladder cancer	0.000183	0.00145	CcSEcCtD
Vemurafenib—Nausea—Gemcitabine—urinary bladder cancer	0.000182	0.00144	CcSEcCtD
Vemurafenib—Vomiting—Cisplatin—urinary bladder cancer	0.000182	0.00144	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000181	0.00143	CcSEcCtD
Vemurafenib—Rash—Cisplatin—urinary bladder cancer	0.000181	0.00143	CcSEcCtD
Vemurafenib—Dermatitis—Cisplatin—urinary bladder cancer	0.00018	0.00143	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—urinary bladder cancer	0.00018	0.00143	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—urinary bladder cancer	0.00018	0.00143	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—urinary bladder cancer	0.000179	0.00142	CcSEcCtD
Vemurafenib—Nausea—Fluorouracil—urinary bladder cancer	0.000179	0.00142	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—urinary bladder cancer	0.000179	0.00142	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000178	0.00141	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—urinary bladder cancer	0.000176	0.0014	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—urinary bladder cancer	0.000174	0.00138	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—urinary bladder cancer	0.000174	0.00138	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—urinary bladder cancer	0.000173	0.00137	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000173	0.00137	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—urinary bladder cancer	0.000172	0.00136	CcSEcCtD
Vemurafenib—Nausea—Cisplatin—urinary bladder cancer	0.00017	0.00135	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—urinary bladder cancer	0.000169	0.00134	CcSEcCtD
Vemurafenib—Cough—Methotrexate—urinary bladder cancer	0.000168	0.00133	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—urinary bladder cancer	0.000167	0.00132	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—urinary bladder cancer	0.000167	0.00132	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—urinary bladder cancer	0.000167	0.00132	CcSEcCtD
Vemurafenib—Rash—Etoposide—urinary bladder cancer	0.000165	0.00131	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—urinary bladder cancer	0.000165	0.00131	CcSEcCtD
Vemurafenib—Headache—Etoposide—urinary bladder cancer	0.000164	0.0013	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—urinary bladder cancer	0.000164	0.0013	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—urinary bladder cancer	0.000164	0.0013	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000163	0.00129	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000163	0.00129	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—urinary bladder cancer	0.000161	0.00128	CcSEcCtD
Vemurafenib—Cough—Epirubicin—urinary bladder cancer	0.000157	0.00124	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000157	0.00124	CcSEcCtD
Vemurafenib—Infection—Methotrexate—urinary bladder cancer	0.000156	0.00124	CcSEcCtD
Vemurafenib—Nausea—Etoposide—urinary bladder cancer	0.000156	0.00123	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000154	0.00122	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—urinary bladder cancer	0.000153	0.00121	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—urinary bladder cancer	0.000153	0.00121	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—urinary bladder cancer	0.000153	0.00121	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000152	0.00121	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000147	0.00116	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—urinary bladder cancer	0.000147	0.00116	CcSEcCtD
Vemurafenib—Infection—Epirubicin—urinary bladder cancer	0.000146	0.00116	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—urinary bladder cancer	0.000145	0.00115	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000144	0.00114	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000143	0.00113	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—urinary bladder cancer	0.000143	0.00113	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—urinary bladder cancer	0.000142	0.00112	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—urinary bladder cancer	0.000142	0.00112	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000141	0.00112	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—urinary bladder cancer	0.000137	0.00109	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—urinary bladder cancer	0.000137	0.00108	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000136	0.00108	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000136	0.00107	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—urinary bladder cancer	0.000135	0.00107	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—urinary bladder cancer	0.000135	0.00107	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000134	0.00106	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000133	0.00106	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—urinary bladder cancer	0.000132	0.00105	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—urinary bladder cancer	0.000128	0.00101	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—urinary bladder cancer	0.000127	0.00101	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000127	0.00101	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—urinary bladder cancer	0.000127	0.001	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—urinary bladder cancer	0.000126	0.000996	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—urinary bladder cancer	0.000124	0.000984	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000124	0.000982	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000118	0.000937	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000117	0.00093	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—urinary bladder cancer	0.000117	0.000929	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—urinary bladder cancer	0.000116	0.000921	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—urinary bladder cancer	0.000116	0.00092	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000116	0.000917	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—urinary bladder cancer	0.000113	0.000893	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—urinary bladder cancer	0.000111	0.00088	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000108	0.000858	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000108	0.000852	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—urinary bladder cancer	0.000107	0.000851	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—urinary bladder cancer	0.000105	0.000835	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—urinary bladder cancer	0.000104	0.000824	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—urinary bladder cancer	0.000104	0.000823	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—urinary bladder cancer	0.000101	0.000797	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.0001	0.000794	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—urinary bladder cancer	9.99e-05	0.000791	CcSEcCtD
Vemurafenib—Rash—Methotrexate—urinary bladder cancer	9.91e-05	0.000784	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—urinary bladder cancer	9.9e-05	0.000784	CcSEcCtD
Vemurafenib—Headache—Methotrexate—urinary bladder cancer	9.84e-05	0.000779	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—urinary bladder cancer	9.76e-05	0.000773	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—urinary bladder cancer	9.72e-05	0.00077	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—urinary bladder cancer	9.62e-05	0.000762	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—urinary bladder cancer	9.35e-05	0.00074	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—urinary bladder cancer	9.33e-05	0.000739	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—urinary bladder cancer	9.31e-05	0.000737	CcSEcCtD
Vemurafenib—Rash—Epirubicin—urinary bladder cancer	9.27e-05	0.000734	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—urinary bladder cancer	9.26e-05	0.000733	CcSEcCtD
Vemurafenib—Headache—Epirubicin—urinary bladder cancer	9.21e-05	0.000729	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—urinary bladder cancer	9e-05	0.000712	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—urinary bladder cancer	8.73e-05	0.000692	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—urinary bladder cancer	8.65e-05	0.000685	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—urinary bladder cancer	8.58e-05	0.000679	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—urinary bladder cancer	8.57e-05	0.000679	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—urinary bladder cancer	8.52e-05	0.000675	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—urinary bladder cancer	8.08e-05	0.00064	CcSEcCtD
Vemurafenib—RAF1—Innate Immune System—PTEN—urinary bladder cancer	2.28e-05	0.000131	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NAT2—urinary bladder cancer	2.28e-05	0.000131	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.26e-05	0.00013	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTP1—urinary bladder cancer	2.26e-05	0.00013	CbGpPWpGaD
Vemurafenib—BRAF—Disease—RHOA—urinary bladder cancer	2.25e-05	0.000129	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.25e-05	0.000129	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.25e-05	0.000129	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TERT—urinary bladder cancer	2.23e-05	0.000128	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—urinary bladder cancer	2.21e-05	0.000127	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.21e-05	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TERT—urinary bladder cancer	2.2e-05	0.000126	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDKN1A—urinary bladder cancer	2.2e-05	0.000126	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PTEN—urinary bladder cancer	2.19e-05	0.000126	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—urinary bladder cancer	2.19e-05	0.000126	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGFR3—urinary bladder cancer	2.19e-05	0.000126	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.18e-05	0.000125	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TERT—urinary bladder cancer	2.18e-05	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EP300—urinary bladder cancer	2.18e-05	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—SRC—urinary bladder cancer	2.12e-05	0.000122	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—urinary bladder cancer	2.1e-05	0.000121	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TYMS—urinary bladder cancer	2.1e-05	0.000121	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERBB2—urinary bladder cancer	2.08e-05	0.00012	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.08e-05	0.00012	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NCOR1—urinary bladder cancer	2.07e-05	0.000119	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTM1—urinary bladder cancer	2.07e-05	0.000119	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.05e-05	0.000118	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGFR3—urinary bladder cancer	2.04e-05	0.000117	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—urinary bladder cancer	2.04e-05	0.000117	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—SRC—urinary bladder cancer	2.03e-05	0.000117	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGFR3—urinary bladder cancer	2.02e-05	0.000116	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGFR3—urinary bladder cancer	2e-05	0.000115	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—urinary bladder cancer	2e-05	0.000115	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ESR1—urinary bladder cancer	1.99e-05	0.000114	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GPX1—urinary bladder cancer	1.99e-05	0.000114	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—KRAS—urinary bladder cancer	1.99e-05	0.000114	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTP1—urinary bladder cancer	1.99e-05	0.000114	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—RRM2—urinary bladder cancer	1.97e-05	0.000113	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ERCC2—urinary bladder cancer	1.95e-05	0.000112	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—KRAS—urinary bladder cancer	1.95e-05	0.000112	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—S100B—urinary bladder cancer	1.95e-05	0.000112	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.91e-05	0.00011	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IGF1—urinary bladder cancer	1.89e-05	0.000108	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.88e-05	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CREBBP—urinary bladder cancer	1.86e-05	0.000107	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—urinary bladder cancer	1.86e-05	0.000107	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.85e-05	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDH1—urinary bladder cancer	1.85e-05	0.000106	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TYMS—urinary bladder cancer	1.85e-05	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—RHOA—urinary bladder cancer	1.84e-05	0.000106	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—urinary bladder cancer	1.83e-05	0.000105	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NCOR1—urinary bladder cancer	1.82e-05	0.000105	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTM1—urinary bladder cancer	1.82e-05	0.000105	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HPGDS—urinary bladder cancer	1.82e-05	0.000105	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO2—urinary bladder cancer	1.82e-05	0.000105	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.81e-05	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—urinary bladder cancer	1.78e-05	0.000102	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CDKN1A—urinary bladder cancer	1.78e-05	0.000102	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTEN—urinary bladder cancer	1.77e-05	0.000102	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.77e-05	0.000102	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTT1—urinary bladder cancer	1.77e-05	0.000102	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.76e-05	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—urinary bladder cancer	1.75e-05	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NCOR1—urinary bladder cancer	1.75e-05	0.000101	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GPX1—urinary bladder cancer	1.75e-05	0.0001	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.75e-05	0.0001	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CREBBP—urinary bladder cancer	1.74e-05	0.0001	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.74e-05	0.0001	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—urinary bladder cancer	1.73e-05	9.95e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RHOA—urinary bladder cancer	1.73e-05	9.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CREBBP—urinary bladder cancer	1.72e-05	9.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1—urinary bladder cancer	1.72e-05	9.88e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ERCC2—urinary bladder cancer	1.72e-05	9.86e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CREBBP—urinary bladder cancer	1.7e-05	9.79e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.7e-05	9.78e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.69e-05	9.73e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EP300—urinary bladder cancer	1.69e-05	9.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—urinary bladder cancer	1.69e-05	9.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—urinary bladder cancer	1.68e-05	9.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—urinary bladder cancer	1.66e-05	9.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.65e-05	9.51e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SRC—urinary bladder cancer	1.65e-05	9.46e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.62e-05	9.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.62e-05	9.3e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—urinary bladder cancer	1.61e-05	9.27e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.59e-05	9.16e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RHOA—urinary bladder cancer	1.57e-05	9.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB2—urinary bladder cancer	1.56e-05	8.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—RHOA—urinary bladder cancer	1.56e-05	8.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—urinary bladder cancer	1.55e-05	8.89e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—RHOA—urinary bladder cancer	1.54e-05	8.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TERT—urinary bladder cancer	1.54e-05	8.86e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.5e-05	8.65e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.5e-05	8.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—urinary bladder cancer	1.49e-05	8.56e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—urinary bladder cancer	1.49e-05	8.54e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—urinary bladder cancer	1.47e-05	8.48e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NQO1—urinary bladder cancer	1.47e-05	8.44e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.46e-05	8.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB2—urinary bladder cancer	1.46e-05	8.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—urinary bladder cancer	1.45e-05	8.34e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—urinary bladder cancer	1.44e-05	8.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB2—urinary bladder cancer	1.44e-05	8.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—urinary bladder cancer	1.43e-05	8.22e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CREBBP—urinary bladder cancer	1.43e-05	8.2e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB2—urinary bladder cancer	1.43e-05	8.2e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.43e-05	8.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGFR3—urinary bladder cancer	1.41e-05	8.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—urinary bladder cancer	1.41e-05	8.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—urinary bladder cancer	1.41e-05	8.09e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—urinary bladder cancer	1.4e-05	8.02e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—urinary bladder cancer	1.38e-05	7.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.38e-05	7.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ESR1—urinary bladder cancer	1.37e-05	7.89e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—urinary bladder cancer	1.36e-05	7.83e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.36e-05	7.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1A—urinary bladder cancer	1.33e-05	7.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTEN—urinary bladder cancer	1.33e-05	7.64e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—urinary bladder cancer	1.32e-05	7.59e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.31e-05	7.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—EP300—urinary bladder cancer	1.3e-05	7.48e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—urinary bladder cancer	1.29e-05	7.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.27e-05	7.32e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.27e-05	7.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EP300—urinary bladder cancer	1.27e-05	7.29e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.27e-05	7.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—urinary bladder cancer	1.27e-05	7.27e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.26e-05	7.22e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—urinary bladder cancer	1.25e-05	7.18e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1A—urinary bladder cancer	1.25e-05	7.16e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—urinary bladder cancer	1.24e-05	7.14e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.24e-05	7.14e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.24e-05	7.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—urinary bladder cancer	1.23e-05	7.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1A—urinary bladder cancer	1.23e-05	7.07e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.23e-05	7.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—urinary bladder cancer	1.23e-05	7.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—urinary bladder cancer	1.22e-05	7.04e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1A—urinary bladder cancer	1.22e-05	7.01e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.22e-05	6.99e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—urinary bladder cancer	1.22e-05	6.99e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.21e-05	6.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREBBP—urinary bladder cancer	1.2e-05	6.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—urinary bladder cancer	1.19e-05	6.83e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EP300—urinary bladder cancer	1.19e-05	6.81e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.19e-05	6.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—urinary bladder cancer	1.18e-05	6.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EP300—urinary bladder cancer	1.17e-05	6.73e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.17e-05	6.72e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EP300—urinary bladder cancer	1.16e-05	6.67e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—urinary bladder cancer	1.16e-05	6.66e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—urinary bladder cancer	1.15e-05	6.62e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TYMS—urinary bladder cancer	1.14e-05	6.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—urinary bladder cancer	1.14e-05	6.54e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—urinary bladder cancer	1.13e-05	6.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—urinary bladder cancer	1.13e-05	6.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NCOR1—urinary bladder cancer	1.13e-05	6.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—urinary bladder cancer	1.12e-05	6.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RHOA—urinary bladder cancer	1.09e-05	6.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—urinary bladder cancer	1.08e-05	6.21e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—urinary bladder cancer	1.08e-05	6.19e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.06e-05	6.1e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ERCC2—urinary bladder cancer	1.06e-05	6.08e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—urinary bladder cancer	1.05e-05	6.02e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—urinary bladder cancer	1.03e-05	5.94e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.03e-05	5.91e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.03e-05	5.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—urinary bladder cancer	1.02e-05	5.87e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—urinary bladder cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—urinary bladder cancer	1.01e-05	5.81e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.01e-05	5.81e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—urinary bladder cancer	1.01e-05	5.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—urinary bladder cancer	1.01e-05	5.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—urinary bladder cancer	9.98e-06	5.74e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.97e-06	5.73e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—urinary bladder cancer	9.95e-06	5.72e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—urinary bladder cancer	9.89e-06	5.69e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.84e-06	5.65e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.84e-06	5.65e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—EP300—urinary bladder cancer	9.72e-06	5.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—urinary bladder cancer	9.56e-06	5.5e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—urinary bladder cancer	9.54e-06	5.48e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.54e-06	5.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—urinary bladder cancer	9.5e-06	5.46e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—urinary bladder cancer	9.43e-06	5.42e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	9.4e-06	5.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—urinary bladder cancer	9.35e-06	5.37e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—urinary bladder cancer	9.32e-06	5.35e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	9.29e-06	5.34e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	9.29e-06	5.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—urinary bladder cancer	9.14e-06	5.25e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—urinary bladder cancer	8.97e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—urinary bladder cancer	8.91e-06	5.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—urinary bladder cancer	8.91e-06	5.12e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.9e-06	5.11e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.74e-06	5.02e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.69e-06	5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—urinary bladder cancer	8.68e-06	4.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—urinary bladder cancer	8.65e-06	4.97e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.62e-06	4.95e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—urinary bladder cancer	8.6e-06	4.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	8.57e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—EP300—urinary bladder cancer	8.55e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—urinary bladder cancer	8.48e-06	4.87e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.29e-06	4.76e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	8.21e-06	4.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EP300—urinary bladder cancer	8.2e-06	4.71e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—urinary bladder cancer	8.11e-06	4.66e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—urinary bladder cancer	8.07e-06	4.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—urinary bladder cancer	8.01e-06	4.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—urinary bladder cancer	7.97e-06	4.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.97e-06	4.58e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—urinary bladder cancer	7.94e-06	4.57e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.93e-06	4.56e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.87e-06	4.52e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.87e-06	4.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CREBBP—urinary bladder cancer	7.75e-06	4.45e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.54e-06	4.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	7.4e-06	4.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—urinary bladder cancer	7.15e-06	4.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—urinary bladder cancer	6.99e-06	4.02e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.96e-06	4e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.66e-06	3.83e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.61e-06	3.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—urinary bladder cancer	6.6e-06	3.79e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.4e-06	3.68e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—urinary bladder cancer	6.35e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.15e-06	3.53e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.08e-06	3.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.08e-06	3.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—urinary bladder cancer	5.87e-06	3.37e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.82e-06	3.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.71e-06	3.28e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.64e-06	3.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—urinary bladder cancer	5.61e-06	3.23e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—urinary bladder cancer	5.53e-06	3.18e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.42e-06	3.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.37e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—EP300—urinary bladder cancer	5.28e-06	3.03e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	5.24e-06	3.01e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.57e-06	2.63e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.44e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.36e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.35e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.18e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.87e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.69e-06	2.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.43e-06	1.97e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.99e-06	1.72e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.85e-06	1.64e-05	CbGpPWpGaD
